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Previewslipases. Importantly, these proteins had
been previously implicated in regulating
the plasma levels of lipids associated
with VLDL particles. These data then set
the stage for the authors to examine
whether XBP1 knockout or ablation via
silencing depresses the levels of plasma
lipids. As hypothesized, decreased
plasma TG and cholesterol were evident
when XBP1 was absent. XBP1 deficiency
also protected against hyperlipidemia in
dyslipidemic mice. Based on these
results, the authors propose XBP1 as a
therapeutic target to reduce plasma lipid
levels.
Together, the companion papers pin-
point the IRE1-XBP1 arm of the UPR as
a target to suppress the production of
circulating atherosclerosis-causing lipids,
a goal that will ultimately affect a disease
that results in one-quarter of all deaths in
the United States. However, enthusiasm
for this approach needs to be calibrated
by potential adverse effects on one or
more of the many targets of this pathway
and by questions that arise from some of
the disparate results in these studies.
Most notably, in So et al. there was408 Cell Metabolism 16, October 3, 2012 ª20decreased lipogenesis and protection
from steatosis in mice that were either
insulin resistant or fed a lipogenic diet,
but in Wang et al. there was mild steatosis
even in chow-fed mice, which was
exacerbated by a lipogenic diet. It is
unclear why Wang et al. (2012) did not
observe the decrease in lipogenesis
reported in So et al. (2012) and Lee et al.
(2008). This discrepancy will need to be
resolved experimentally before clinical
extensions can be contemplated, given
that an agent that reduces plasma lipid
levels while concurrently promoting
steatosis is unlikely to gain U.S. Food
and Drug Administration approval. More
fundamentally, it will be interesting to
pursue why neither study found adverse
effects on general protein production
by the liver despite the loss of this one
arm of the UPR, which is a key quality
control process in the ER for secretory
proteins. Nonetheless, by identifying
components of the UPR pathway that
regulate the composition and plasma
levels of VLDL lipids, these reports
provide a wealth of provocative informa-
tion that will enliven the field of lipoprotein12 Elsevier Inc.metabolism from both basic science and
therapeutic perspectives.ACKNOWLEDGMENTS
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Recent research suggests that obesitymay be influenced not only by dietary and genetic risk factors, but also
by the trillions of microorganisms inhabiting our gastrointestinal tract. Consistent with this notion, Cho et al.
(2012) use mice to demonstrate that subtherapeutic antibiotic treatment promotes adiposity.Humans and other mammals have co-
evolved with trillions of microorganisms
that thrive in and on our bodies. The
ensuing host-microbial interactions are
often beneficial; however, disturbance
of this delicate balance is thought to
lead to an increased risk of disease
(Dethlefsen et al., 2007). Recent efforts
have extensively characterized the com-
position of the microbial communities
found in multiple body habitats (Consor-tium, 2012), but we are only just begin-
ning to discover the unintended conse-
quences of a Western lifestyle on our
microbial partners (Blaser and Falkow,
2009). In particular, orally administered
broad-spectrum antibiotics have a clear
potential to influence the microbes inhab-
iting our gastrointestinal tract (the gut
microbiota).
But what are the functional conse-
quences of the widespread use of antibi-otics? One possible ramification is altered
host energy balance. A number of studies
have linked the gut microbiota to
obesity (Ba¨ckhed et al., 2004; Turnbaugh
et al., 2006), and low-dose antibiotics
have been used for decades to enhance
growth and feed efficiency in farm
animals (Jukes, 1971). The mechanisms
through which antibiotics promote this
phenomenon and whether the increasing
use of antibiotics in children contributes
Figure 1. The Many Effects of Subtherapeutic Antibiotic Treatment
on Young Mice
Relative to controlmice, STAT results in similar total bodyweight but increased
adiposity, dietary energy harvest, bonemineral density (BMD), and short-chain
fatty acid (SCFA) levels. These phenotypic differences were associated with
changes to the gut microbial community, host lipid metabolism, and gut
hormone signaling. Future studies promise to elucidate the mechanistic basis
for these changes.
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Previewsto a predisposition to obesity
later in life are currently
unknown. Tractable model
systems are needed to tease
apart the many confounding
factors potentially influenc-
ing host energy balance.
Recently, work done by
Martin Blaser and colleagues
(Cho et al., 2012) has made
an important first step toward
addressing these issues,
exposing young mice to
various low-dose antibiotic
treatments for 7 weeks, re-
sulting in increased adiposity
(Figure 1).
The microbial response
to subtherapeutic antibiotic
treatment (STAT) was evi-
denced by an altered com-
munity structure rather thantotal abundance. A shift toward an
increased Firmicutes to Bacteroidetes
ratio has been associated with an obese
state (Ley et al., 2005; Turnbaugh
et al., 2006). Surprisingly, this shift was
evident after coadministration of penicillin
and vancomycin, two primarily Gram-
positive (i.e., Firmicutes) targeting com-
pounds, and not after administration
of either antibiotic alone. Chlortetracy-
cline, another antimicrobial that acts
through a different mechanism, also
caused this shift. Given the different
modes of action and range of these anti-
microbials, this calls into question how
these various antibiotics affect the micro-
bial community and to what degree indi-
vidual microbial taxonomic groups, or
multiple groups working in concert, might
directly contribute to the development of
adiposity.
One possibility is that the disrupted
gut microbiota following STAT has an
enhanced ability to harvest energy from
the diet, through microbial production
of short-chain fatty acids (SCFAs), to
provide substrates for storage into
adipose tissue, as proposed for obesity
(Turnbaugh et al., 2006). The authors
observed that STAT led to increased over-
all caloric extraction from thediet, together
with increased SCFA concentrations.
Although the four treatment options had
variable effects on microbial community
structure and SCFA levels, all of these
treatments resulted in some degree of
increased adiposity, suggesting that theremay be a common host response to
multiple types of perturbations to the gut
microbiota. To determine whether a link
could be made between the gut micro-
biota,SCFA levels, andadiposity, changes
in downstream host genes for hepatic
lipidmetabolismwere quantifiedbymicro-
array and quantitative PCR. Some genes
coding for lipogenesis and triglyceride
synthesis were upregulated, but no
phenotypic signs of hepatic steatosis or
differences inmetabolic activity of visceral
adipose tissues were observed. Increased
serum levels of a secreted gastrointestinal
hormone (GIP) may be an alternative
contributor to adiposity. Further experi-
ments to clarify these putative mecha-
nisms and experiments in germ-free mice
exposed to STAT are necessary to rule
out any direct effects these compounds
may have on host physiology.
Interestingly, unlike what is seen in
livestock, STAT had a minimal effect on
overall body weight and feed efficiency
in mice. The authors did report an
accelerated growth rate within the first
week of STAT and an increase in bone
mineral density after 3 weeks. It is possi-
ble that this initial accelerated growth
toward maturity is sufficient to promote
fat deposition.
This work raises many questions as to
the potential links between antibiotic
exposure and adiposity. Given that antibi-
otic use has a greater effect on growth in
young animals than mature animals
(Jukes, 1971), to what degree does theCell Metabolism 16, October 3,effect of STAT depend on
the age of the mice? Is this
phenomenon unique to early
life? How much, if at all,
does the effect depend on
the specific antibiotics used
and their relative propor-
tions? Do antibiotics influ-
ence host energy balance
through direct effects on the
host, or are the observed
phenotypes entirely depen-
dent on the gut microbiota?
To what degree does the
prevalence and horizontal
transfer of antibiotic resis-
tance genes influence the
increase in adiposity? How
dependent are these effects
on other factors known to
influence the gut microbiota
and host energy balance?For example, would consumption of a
high-fat/high-sugar ‘‘Western’’ diet exac-
erbate the effects of STAT? Also, while
much of the attention devoted to the role
of the microbiota in regulating host metab-
olism is focused on an increase in dietary
energy harvest, what impact could the mi-
crobiota have on the other side of
the energy balance equation? Is there an
effect of the gut microbiota on energy
expenditure?
Perhaps most importantly, this work
provides a tractable animal model to
investigate these and many other burning
questions regarding the energetic conse-
quences of perturbations to the gut
microbiota. Of note, another recent study
performed by Blaser and colleagues
supports the relevance of these findings
to humans: infants exposed to antibiotics
within the first 6 months of life had in-
creased body mass later in life (Trasande
et al., 2012). Together, these results
underscore a view of human metabolism
as a composite of our human and micro-
bial genomes and the critical need for
a better understanding of how these
host-microbial interactions contribute to
health and disease in the presence or
absence of a wide range of orally adminis-
tered therapeutics.
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Humans with dominant-negative (DN) mutations in PPAR-Y develop early onset hypertension. A recent
study by Pelham et al. (2012) shows that loss of PPAR-Y repression of the Rho kinase pathway leads
to altered vascular function via a smooth-muscle-dependent pathway that is independent of NO and
oxidant stress.PPAR-Y is a ligand-activated transcrip-
tion factor that is targeted by the thiazoli-
dinedione (TZD) class of antidiabetes
medications and is known to be important
in the regulation of adipogenesis and
type II diabetes (Beyer et al., 2008).
Activation of PPAR-Y by TZD drugs
improves insulin sensitivity and lowers
blood pressure in type II diabetics; how-
ever, individuals with dominant-negative
(DN) mutations of PPAR-Y not only
present with type II diabetes and severe
insulin resistance, but also exhibit early
onset hypertension via unknown mecha-
nisms (Barroso et al., 1999). This early
onset hypertension is mimicked in trans-
genic mice with a similar mutation. In
this issue, Pelham et al. (2012) utilize
one of these transgenic models to identify
mechanisms by which a DN mutant
form of PPAR-Y, expressed specifically
in the smooth muscle, causes enhanced
contraction and impaired vascular relaxa-
tion, leading to hypertension. The study
reveals a pathway in which smooth
muscle-specific PPAR-Y and Cullin-3, a
member of the E3-ubiquitin ligase com-
plex, participate in the regulation of vas-
cular smooth muscle tone and, possibly,
in the regulation of arterial blood pressure.
The authors find that mice with the DN
PPAR-Y mutation exhibit increased vas-cular contraction, impaired relaxation,
and elevated blood pressure similar to
the phenotypes found in various forms of
human hypertension; and that these alter-
ations are associated with increases in
RhoA and Rho-kinase activity. They
further show that this upregulation of the
Rho kinase pathway is related to reduced
expression and decreased neddylation
(conjugation of the ubiquitin-like protein
Nedd8) to Cullin-3, which normally
reduces the expression and activity of
RhoA by promoting its degradation in
the proteasome. Phenotypes similar to
those in mice expressing the DN PPAR-Y
mutation could be produced in wild-type
mice by treating them with a pharmaco-
logical agent (MLN4924) that inhibits the
neddylation of Cullin-3.
One gap in existing knowledge is the
mechanism by which Cullin-3 is regulated
by PPAR-Y. Cullin-3 is a cullin-RING E3
ubiquitin ligase complex scaffold protein
that regulates the turnover of RhoA
(Chen et al., 2009). The present study
provides evidence that Cullin-3 is down-
regulated in mice with the DN PPAR-Y
mutation, and that this occurs via sup-
pression of RhoBTB1, a novel PPAR-Y
target gene that may regulate the target-
ing of some Cullin-3 substrates, including
RhoA, for proteasomal degradation viathe Cullin-3 E3 RING ubiquitin ligase
complex.
A particularly attractive feature of the
study is the linking of this pathway to
vascular regulation in intact blood
vessels, in this case the aorta, rather
than exclusive use of cultured cell
models. The authors found that vascular
relaxation in response to acetylcholine
and the NO donor sodium nitroprusside
were impaired in mice harboring the DN
mutation of PPAR-Y. The investigators
provide convincing evidence that altered
vascular function in aortas of these mice
is mediated by a mechanism other than
changes in NO availability or elevated
vascular oxidant stress. This finding is
significant, given the multitude of studies
showing the importance of NO and reac-
tive oxygen species as major mediators
of pathophysiological changes in multiple
cardiovascular disorders. Other mecha-
nisms of potential importance have
seldom been sought.
The authors also show that systemic
administration of MLN4924 leads to an
elevated blood pressure in wild-type
mice. This is a potentially important
finding because it provides support for a
whole-body effect of the Cullin-3 mecha-
nism, a proof of concept that cannot be
obtained with in vitro studies of molecular
